Stock VERV VERVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Verve Therapeutics, Inc.

Equities

VERV

US92539P1012

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 01/05/2024 BST 		5-day change 1st Jan Change
6 USD -0.17% Intraday chart for Verve Therapeutics, Inc. -8.81% -56.96%
04-03 Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating MT
04-02 Sector Update: Health Care Stocks Slide Late Afternoon MT

Business Summary

Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.

Number of employees: 255

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
2 100.0 % 12 100.0 % +505.77%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
2 100.0 % 12 100.0 % +505.77%

Managers

Managers TitleAgeSince
Sekar Kathiresan FOU
 Founder 52 31/12/17
Allison Dorval DFI
 Director of Finance/CFO 48 28/11/21
Andrew Ashe PSD
 President 57 31/07/18
Jason Politi CTO
 Chief Tech/Sci/R&D Officer 47 31/01/21
Richard Falzone CTO
 Chief Tech/Sci/R&D Officer 50 31/03/21
Joan Nickerson ADM
 Chief Administrative Officer 56 31/03/21
Troy Lister CTO
 Chief Tech/Sci/R&D Officer - 30/04/22
Andrew Bellinger CTO
 Chief Tech/Sci/R&D Officer - 30/09/19
Fred Fiedorek CTO
 Chief Tech/Sci/R&D Officer 69 17/09/23
Andrew Sheely CTO
 Chief Tech/Sci/R&D Officer - -

Members of the board

Members of the board TitleAgeSince
Burt Adelman FOU
 Founder 71 31/12/17
Lonnel Coats BRD
 Director/Board Member 58 07/08/22
Michael MacLean BRD
 Director/Board Member 58 30/04/21
Sheila Mikhail BRD
 Director/Board Member 57 31/03/21
Krishna Yeshwant BRD
 Director/Board Member 46 31/07/18
Alexander Cumbo BRD
 Director/Board Member 53 08/06/22
Sekar Kathiresan FOU
 Founder 52 31/12/17

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 83,922,819 77,526,974 ( 92.38 %) 0 92.38 %

Shareholders

NameEquities%Valuation
ALPHABET INC.
15.72 %
12,349,086 15.72 % 164 M $
ARK Investment Management LLC
7.690 %
6,040,476 7.690 % 80 M $
Vanguard Fiduciary Trust Co.
6.966 %
5,471,930 6.966 % 73 M $
James R Singer
6.365 %
5,000,000 6.365 % 66 M $
BlackRock Advisors LLC
5.290 %
4,155,026 5.290 % 55 M $
Federated Global Investment Management Corp.
5.067 %
3,980,372 5.067 % 53 M $
STATE STREET CORPORATION
4.923 %
3,866,764 4.923 % 51 M $
T. Rowe Price Investment Management, Inc.
4.041 %
3,174,352 4.041 % 42 M $
Fidelity Management & Research Co. LLC
3.913 %
3,073,841 3.913 % 41 M $
Casdin Capital LLC
3.831 %
3,009,094 3.831 % 40 M $

Company contact information

Verve Therapeutics, Inc.

201 Brookline Avenue Suite 601

02215, Boston

+

http://www.vervetx.com
address Verve Therapeutics, Inc.(VERV)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Verve Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
6 USD
Average target price
31.22 USD
Spread / Average Target
+420.37%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
VERVE THERAPEUTICS, INC. Stock Verve Therapeutics, Inc.
-56.96% 504M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.67% 42.19B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.15B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.55% 24.63B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.66% 18.2B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.96% 12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.57% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+16.03% 10.4B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.80% 9.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. VERV Stock
  4. Company Verve Therapeutics, Inc.